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Summary The aims of the present study were to characterise an assay for cAMP-binding proteins in ovarian
cancer and then to measure levels in a series of tumours with a view to developing a potential prognostic
indicator for this disease. Levels and types of binding proteins have been measured in cytosols from 50 ovarian
tumours. Binding proteins were detected in all tumours but, as calculated from Scatchard analysis, binding
levels ranged from 267 to 12,037 fmol per mg of cytosol protein (mean value of 4248 fmol mg-'). Dissociation
constants of binding varied between 0.4 x 10-8 and 5.9 x 10-8 (mean value 2.3 x 10-8). Types of binding
protein were detected by incubation with the photoaffinity ligand 8-N3-[32P]cAMP, followed by polyacrylamide
gel electrophoresis and autoradiography. Labelled proteins with molecular weights of 52, 48, 43, 39 and
37 kDa were identified in the cytosols. The proportion and pattern of bands detected varied between different
cytosols. The significance of these findings awaits clinical follow-up of the patients.
Cyclic adenosine 3',5'-monophosphate (cAMP) is an impor-
tant second messenger which is involved in signalling path-
ways controlling cell proliferation and differentiation (Pastan
et al., 1975; Prasad, 1975; Cho-Chung, 1980; Puck, 1987;
Cho-Chung et al., 1990). Cyclic AMP appears to exert its
major effects through type A protein kinase (PKA), a tetra-
meric holoenzyme made up of two regulatory (R) and two
catalytic (C) subunits. The protein kinase A regulatory
subunits, also known as cAMP-binding proteins, may exist as
different subtypes, which are referred to as the RI and RII
isoforms. It has been suggested that levels and types of
binding proteins may change during malignant transforma-
tion and may be associated with differences in tumour
behaviour. For example, differential expression of the
independent isoenzymes (RI or RII) may influence the
regulation of tumour cell growth and differentiation
phenotype (Tortora et al., 1990; Cho-Chung, 1990). Further-
more, levels of cAMP-binding proteins in rodent mammary
carcinomas (Bodwin & Cho-Chung, 1978; Bodwin et al.,
1980; Cho-Chung et al., 1981) vary according to the degree
of autonomy and growth status of the tumour. More
recently, it has been reported that high levels of tumour
cAMP-binding proteins are associated with poor prognosis in
patients with breast cancer (Miller et al., 1990). To our
knowledge, the involvement of cAMP-binding protein levels
in the behaviour of ovarian cancer has not yet been investi-
gated, although there are no reliable prognostic factors for
this malignancy. The aims of the present study were to
characterise an assay for cAMP-binding proteins in ovarian
cancer and then to measure levels in a series of tumours with
a view to correlating them with prognosis of the disease.
Materials and methods
Reagents
5',8'-[3H]Adenosine 3',5'-cyclic phosphate ammonium salt
(45-56 Ci mmol ') was obtained from Radiochemical Centre,
Amersham, 8-azidoadenosine 3',5'-cyclic [32P]monophosphate
(56-62 Ci mmol-') from ICN Radiochemicals and radioinert
adenosine 3',5'-cyclic phosphate sodium salt, guanosine 3',5'-
cyclic phosphate sodium salt, adenosine 5'-monophosphate
sodium salt, adenosine 5'-triphosphate disodium salt and
8-azidoadenosine 3',5'-cyclic monophosphate free acid were
obtained from Sigma (Poole, UK).
Tissues
Tumour, obtained at laparotomy from 50 patients with his-
tologically proven ovarian cancer, was immediately placed on
ice and transported at 0°C to the laboratory. Aliquots were
then snap frozen and stored in liquid nitrogen until use.
Histological examination of the tumours showed 26 to be
serous carcinomas, ten endometrioid carcinomas, four
mucinous carcinomas, three clear cell carcinomas, one
teratoma, two of mixed pathology and four of borderline
malignancy.
Cytosolpreparation
Specimens were processed on ice. Aliquots of tumour
(200 mg) were minced with scissors and homogenised (Silver-
son) in 1: 10 (w/v) buffer A (20 mM Tris, 0.25 M sucrose,
2 mM magnesium chloride, 1 mM calcium chloride, 10 mM
potassium chloride, 16.26 mM hydrochloric acid, pH 7.5).
The resulting homogenate was centrifuged for I h at
105,000 g in a Beckman L7-65 Ultracentrifuge at 4°C. The
supernatant was retained and used as the cytosol in cAMP-
binding protein assays.
Cyclic AMP-binding assay
Unless stated otherwise, cytosol (50 gd) was incubated over-
night at 4°C with 5',8'-[3H]cyclic AMP (100 LI of 25 nM) in
buffer A (to give a final concentration in the incubation of
10 nM) and 100 of buffer B (55 mM potassium phosphate
to which 11 mM theophylline was freshly added) containing
radioinert cyclic AMP (Sigma) at increasing final concentra-
tions of 0, 10, 20, 40, 80, 10,000 nM. Bound and free cAMP
were then separated by filtration through Millipore HAWP
0.45 gtm filters. Filters were washed in assay buffer C (buffer
B with addition of 10 mm magnesium chloride) and transfer-
red to counting vials containing Micellar fluor NE260 liquid
scintillant (NE Technology Ltd). The vials were incubated at
37'C for 2 h and radioactivity was measured using a Tricarb
liquid scintillation counter (Packard). Results were analysed
by Scatchard analysis (Scatchard, 1949) and binding ex-
pressed as fmol of cAMP bound per mg of cytosol pro-
tein.
Measurement ofcytosolprotein
Cytosol protein content was measured spectrophotomet-
rically (Bradford, 1976) using bovine serum albumin as a
standard.
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Specificity ofbinding
The specificity of the cAMP-binding assay was determined by
incubating an ovarian tumour cytosol with [3H]cAMP in the
absence and presence of increasing concentrations of one of
the following radioinert nucleotides: cAMP, cGMP, AMP or
8-azido-cAMP, (0, 0.005, 0.05, 5, 50, 50011M). With respect
to all other parameters, the binding assays were carried out
as described previously.
Typing ofcAMP-binding proteins usingphotoaffinity labelling
Different types of binding proteins were determined by
photoaffinity labelling with 8-azidoadenosine 3',5'-cyclic
[32P]monophosphate. Cytosol samples (50 il) were prepared
as described above and incubated with 8-N3-[32P]cAMP
(151l), 15 ,sl of 0.27M morpholine ethane sulphonic acid
(Sigma) and 53 mM magnesium chloride in a 0.4cm well
microtitre plate at room temperature for 1 h in the dark. The
contents of the wells were then UV irradiated for 30 s at
254 nm by placing a Mineralight UVS-11 hand lamp directly
over the plate, as adapted from the method of Pomerantz et
al. (1975).
The reactions were stopped by the addition of sodium
dodecyl sulphate (SDS) buffer (3% SDS, 15% 2-mercapto-
ethanol, 30mM Tris, 30% glycerol, 1% bromophenol blue).
The samples were heated to 90°C for 3 min and the proteins
resolved electrophoretically on a 12% SDS-PAGE gel for
3-4 h at 35 mA, according to the method of Laemmli (1970).
Radioactively labelled 14C molecular weight markers were
run with each gel. After electrophoresis, the gels were fixed
overnight in 40% methanol, 10% acetic acid, 10% glycerol,
then dried under vacuum in a gel drier (Model 583-Biorad).
The dried gels were then exposed to preflashed X-ray film
(Kodak X-omat AR or Fuji) for 5-15 h at -80°C in
autoradiography cassettes fitted with intensifier screens (Hi-
speed X-Genetic Research International). Autoradiograms
were processed in Kodak X-ray developer and fixer.
Results
Assay conditions
To determine the effects of time and temperature on binding,
tumour cytosols were incubated with [3H]cAMP in the
absence and presence of 10,000 nM radioinert cAMP for
varying times, either at room temperature or at 4°C. A
typical result is shown in Figure 1. Binding at room
temperature rose with time of incubation to a maximum after
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90min and levels fell thereafter. In contrast, incubation at
4'C produced increased binding for up to 90 min (which was
lower than that observed by incubation for the same time at
room temperature). There was then a transient fall in binding
but levels subsequently increased up to a maximum at
around 24 h. Since maximal binding was consistently
observed by incubating tumour cytosols in the [3H]cAMP for
24 h at 4°C, these conditions were used in all subsequent
experiments. Under these conditions the amount of cAMP
binding appeared linear with protein concentration of the
cytosols as determined by serial dilution (Figure 2). Protein
concentration of cytosols as determined by the Bradford
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Figure 2 The effect of cytosol dilution on the binding of
[3H]cAMP to cytosols of two ovarian tumours. Cytosols were
prepared as described in Materials and methods and serially
diluted as indicated. Initial concentration of cytosols were
4.04 mgml1-I (open squares) and 2.41 mgml-' (shaded squares).
The diluted cytosols were incubated overnight at 4C with in-
creasing concentrations of radioinert cAMP. The data were
analysed by Scatchard plot and each point represents the max-
imum number of binding sites for each system.
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Figure 1 The effect of time and temperature on the binding of
[3H]cAMP to the cytosol of an ovarian tumour. Incubation was
carried out at room temperature (open squares) or 4°C (shaded
circles). Specific binding is expressed as the radioactivity of
[3H]cAMP bound to tumour cytosol in the absence of cold com-
petitor (radioinert cAMP) minus that bound in the presence of
excess (10,000 nM) cold competitor. Further assay conditions are
described in Materials and methods.
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Figure 3 The effect of radioinert nucleotides on the binding of
[3H]cAMP to a cytosol of ovarian cancer. Assay conditions are
described in Materials and methods. Data are plotted as a,
radioactivity bound, b, according to Scatchard (1949).
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assay appears to deviate from expected values at cytosol
concentrations below 1.Omgm1- , therefore all assays were
performed with cytosols having > 1.0 mg ml-' protein. The
effect of radioinert cAMP on the binding of [3H]cAMP is
shown in Figure 3a. Low concentrations of radioinert cAMP
were able to compete with [3H]cAMP for binding, leaving
only a low level of non-specific binding in the presence of a
thousand-fold excess of competitor. The data plotted accord-
ing to Scatchard (1949) showed that the dissociation constant
of binding (KD) was about 10-8 M (Figure 3b).
Specificity ofbinding
Tumour cytosols were incubated with [3H]cAMP and a wide
range of concentrations of radioinert cAMP, cGMP, 8-azido
cAMP, AMP and ATP (Figure 4). At nanomolar concentra-
tions both cAMP and its 8-azido analogue were able to exert
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Table I Levels and dissociation constants of cAMP-binding
proteins in cytosols of 50 ovarian cancers
Level Dissociation
(fmol per mg of cytosol constant
protein) (M X 10-8)
Mean ± s.d. 4248 ± 2758 2.3 ± 1.24
Range 267-12037 0.4-5.9
Molecular weight (kDa)
52
48>Z
43---
395
37{
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Figure 6 Photoaffinity labelling ofcAMP-binding proteins in ten
ovarian cytosols. Proteins with molecular weights of 52, 48, 43,
39 and 37 kDa were detected. Assay conditions are described in
Materials and methods.
substantial competition on the radioligand, whereas all the
other nucleotides produced negligible competition. Further-
more, even at the highest concentrations employed AMP and
ATP caused little displacement of [3H]cAMP binding.
Figure 4 The effect of various radioinert nucleotides on the
binding of [3H]cAMP to a cytosol of ovarian cancer. Assay
conditions are described in Materials and methods and data are
plotted as radioactivity bound (c.p.m.) against concentration of
cold competitor (gM). AMP is represented by open circles, ATP
by shaded circles, cyclic AMP by open squares, cyclic GMP by
open triangles and 8-azido cAMP by shaded squares.
.5
cn
a)
-
0
._
CL
.0
5.
0
0
14,000 -
12,000 -
10,000 -
8,000 -
6,000 -
4,000 -
2,000 -
0
0
0
0
0
*
S. 0
0@
000 *-
*0
0.
0so
0 00 0
*-.
I.
Figure 5 Levels of cAMP-binding proteins in cytosols of 50
primary ovarian cancers. Individual ovarian tumours are shown.
The horizontal line represents the mean value of cyclic AMP
binding.
Values in ovarian cancer cytosols
Cytosols from 50 ovarian cancers were assayed for cAMP-
binding proteins. The results are presented in Table I, and
the concentrations of binding sites in individual tumours are
plotted in Figure 5. All tumours showed cAMP binding, but
levels varied greatly between individual tumours, from 267 to
12,037 fmol per mg of cytosol protein and dissociation con-
stants for binding ranged between 0.4 and 5.9 x 1-0 M.
Photoaffnity labelling ofcAMP-bindingproteins in ovarian
tumour cytosols
Tumour cytosols were labelled with 8-azidoadenosine 3',5'-
cyclic [32P]monophosphate to identify the different types of
cAMP-binding proteins present. Proteins of 52, 48, 43, 39
and 37 kilodaltons were identified in the cytosols, the propor-
tion and pattern of which varied between the different
tumour cytosols. To illustrate this, results from the first ten
tumours examined are shown in Figure 6 and indicate, for
example, that cytosols 1 and 6 predominantly express the
48 kDa protein, whereas cytosols 2 and 5 display the 52 kDa
form.
Discussion
This is the first report of cAMP-binding protein
measurements in human ovarian cancers. The study was
prompted by work previously carried out on human breast
cancers (Miller et al., 1990) indicating a link between levels
of cAMP-binding proteins and eventual outcome of the
disease. The results showed that high cAMP-binding protein
levels are an indicator of poor prognosis. In contrast, inCYCLIC AMP BINDING IN OVARIAN CANCER 189
colorectal tumours low levels of binding appear to be
associated with markers of poor prognosis such as advanced
Dukes stage and poor histological grade (Bradbury et al.,
1991). As a prelude to an evaluation of the clinical utility of
cAMP-binding measurements in ovarian cancer, the present
paper describes the characterisation of an assay that may be
used routinely to assess levels of binding protein in this
tumour type.
The method used involves incubating tumour cytosols with
[3H]cAMP in the absence and presence of increasing concen-
trations of radioinert nucleotide. Maximum binding was
observed at 4°C after a 24h incubation, and under these
conditions binding was linearly correlated with cytosol pro-
tein concentration and appeared to be specific for cAMP and
its analogues. It should be noted that these incubation condi-
tions are different from those employed for breast cancers in
other studies (3 h at room temperature). However, the pres-
ent studies on ovarian cancer consistently demonstrate that
incubation times beyond 2 h at room temperature are associ-
ated with decreases in activity. This may be an inherent effect
due to decreased stability of the ovarian binding proteins or
increased proteolytic degradation. Interestingly, at 4°C, plots
of binding vs time invariably showed a transient dip in
binding at around 90 min, and this suggests that the binding
curve is composed of more than one component. This would
be consistent with the results from photoaffinity labelling,
which identified binding proteins differing in molecular
weights.
Using the method as defined, cytosols of 50 human
ovarian cancers were assayed for levels of cAMP-binding
proteins. All possessed binding activity, levels varying from
267 to 12,037 fmol per mg of cytosol protein (mean value of
4248 fmol mg-'). These results fall within the range of
human breast cancer cytosols reported by Miller et al. (1985)
and are higher than those reported for a series of colorectal
cancers using the same methodology. The mean dissociation
constant of 2.4 X 10-8 M is also in keeping with data from
previous work on human breast cancers (Miller et al., 1985)
and work reported for binding proteins in other tumours
(Cho-Chung et al., 1978).
Photoaffinity labelling of cAMP-binding proteins in the
same ovarian cytosols displayed proteins with molecular
weights of 52, 48 and 37 kDa similar to proteins that have
been previously characterised in other tissues. Certain
tumours also possessed binding proteins with molecular
weight of either 43 or 39 kDa. The 48 and 52 kDa species
probably correspond to the regulatory subunits of protein
kinase A (RI and RII respectively), which have been charac-
terised in different tissues (Eppenberger et al., 1980; Tortora
et al., 1989; Bradbury et al., 1991; Miller et al., 1993). The
37 kDa protein has been suggested to be a product resulting
from proteolytic degradation of the regulatory subunits, and
the relatively high levels of this protein are consistent with
our suspicion that ovarian tumour cytosols are more. likely to
display proteolytic activity than, for example, breast cancer.
Although the identification of the binding proteins has not
been completely defined, it is of interest that individual
ovarian cancers may exhibit not only different levels of
cAMP binding but also variations in patterns of binding.
While the significance of differences in binding pattern is as
yet unclear, it has been suggested that the RI and RII
proteins differentially regulate systems which programme cel-
lular proliferation and differentiation. It will thus be impor-
tant to define the factors that influence both level and type of
cAMP-binding protein within ovarian cancers, and these are
the subject of continuing investigation. However, the obvious
differences between individual ovarian cancers and our pub-
lished work on breast cancer which suggests that these
parameters are associated with differences in tumour
behaviour and prognosis indicates that further research on
the cAMP-dependent protein kinase A system in ovarian
cancer is merited.
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